Clinical Trials Logo

Clinical Trial Summary

The primary study objectives are 1. to evaluate the safety and tolerability profiles of DCB-BO1301 and to determine the maximum tolerated dose (MTD) of DCB-BO1301 as add-on therapy to dacarbazine in subjects with advanced melanoma (Phase I) 2. to evaluate the efficacy profile of DCB-BO1301 at MTD or lower dose level as add-on therapy to dacarbazine in subjects with advanced melanoma in terms of progression free survival (Phase IIa)

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02994498
Study type Interventional
Source Chung Mei Biopharma Co., Ltd
Contact Leon YZ Zhan, MS
Phone +886-4-2329-0578
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date March 2023
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT01621490 - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma Phase 1
Completed NCT02177110 - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed NCT00197912 - Dendritic Cell Based Therapy of Malignant Melanoma Phase 1/Phase 2
Recruiting NCT04165967 - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma Phase 1
Recruiting NCT04495257 - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Phase 1
Not yet recruiting NCT03989895 - Arm 2: Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Advanced Melanoma Phase 1
Not yet recruiting NCT04951583 - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma Phase 2
Not yet recruiting NCT03990493 - Arm 3: Intratumoral Injection of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced Melanoma Phase 1
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Terminated NCT01453361 - Phase II FANG™ in Advanced Melanoma Phase 2
Active, not recruiting NCT02965716 - Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Phase 2
Recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT02402699 - Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan N/A
Recruiting NCT01614301 - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma Phase 1/Phase 2
Active, not recruiting NCT03086174 - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma Phase 1
Recruiting NCT03917069 - Nab-PCE vs PC for MM After Failure of Anti-PD-1 Phase 2
Recruiting NCT03818893 - Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII Phase 2
Recruiting NCT03502330 - APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Phase 1
Active, not recruiting NCT02650986 - Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Phase 1/Phase 2